Baseline Predictors of an Early Virologic Response (EVR) in Previously Untreated Patients Undergoing Boceprevir (BOC) Triple Therapy for HCV Genotype 1 Infection in German Real-Life

Background: The achievement of EVR during triple therapy of chronic HCV genotype 1 (G1) infection with BOC has been identified as predictor of high SVR rates of up to 90% as well as a predictor to shorten triple therapy to 24 weeks. The present interim analysis of the NOVUS observational study was aimed to investigate EVR during BOC triple therapy in German real-life and to identify baseline predictors of EVR.